Previous 10 | Next 10 |
Newly Released Clinical Data Demonstrates Substantial Improvement in Overall Health-Related Quality of Life in Patients with Painful Diabetic Neuropathy Treated with Nevro HFX Spinal Cord Stimulation Therapy PR Newswire High-Frequency 10 kHz Therapy Provided Substant...
Nevro is the top pure play spinal cord stimulation [SCS] company with three major industry competitors. Nevro's recent FDA approvals for its high frequency SCS system in treatment of painful diabetic neuropathy and non-surgical refractory back pain are game changers. The pandemic ...
Clinical Data Presented at American Diabetes Association 82nd Scientific Sessions Reinforce Significant and Durable Benefits of Nevro's HFX 10 kHz Therapy PR Newswire SENZA-PDN Randomized Controlled Trial Results From Original 10 kHz Arm Demonstrate Significant and S...
Nevro Announces SENZA-PDN Clinical Data Presentations at the American Diabetes Association 82nd Scientific Sessions PR Newswire Poster Presentation to Include 24-Month Follow-Up Results from Original 10 kHz Arm of SENZA-PDN Randomized Controlled Trial SEN...
Nevro Corp. (NVRO) Q1 2022 Results Conference Call May 4, 2022 4:30 PM ET Company Participants Julie Dewey - Corporate Communications and Investor Relations Officer Keith Grossman - Chairman, Chief Executive Officer and President Rod MacLeod - Chief Financial Officer Conference Call Participa...
The following slide deck was published by Nevro Corp. in conjunction with their 2022 Q1 earnings call. For further details see: Nevro Corp. 2022 Q1 - Results - Earnings Call Presentation
Nevro press release (NYSE:NVRO): Q1 GAAP EPS of -$0.98 beats by $0.12. Revenue of $87.84M (-0.9% Y/Y) beats by $1.65M. Provides Second Quarter 2022 Revenue Guidance of $103 Million to $106 Million vs. $104.36M consensus; Reiterates Full-Year 2022 Revenue Guidance of $415 Million to $430 ...
Nevro Reports First Quarter 2022 Financial Results, Provides Second Quarter 2022 Guidance and Reiterates Full-Year 2022 Guidance PR Newswire REDWOOD CITY, Calif. , May 4, 2022 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), delivering comprehensive, life-c...
Nevro to Report First Quarter 2022 Financial Results PR Newswire Company to Host Conference Call on Wednesday, May 4, 2022 at 1:30 pm PT / 4:30 pm ET REDWOOD CITY, Calif. , April 6, 2022 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO...
Nevro (NVRO +6.8%) stock edged higher after the medical device maker disclosed that CEO and chairman Keith Grossman bought 3.2K shares at $63.59 worth ~$200K. Grossman now holds ~169.3K shares in NVRO. For further details see: Nevro stock rises after CEO buys shares worth $200K
News, Short Squeeze, Breakout and More Instantly...
Nevro to Report Second-Quarter 2024 Financial Results and Host Earnings Conference Call on August 6, 2024 PR Newswire REDWOOD CITY, Calif. , July 9, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company delivering comprehensive, life-chan...
Nevro to Present at Truist Securities MedTech Conference PR Newswire REDWOOD CITY, Calif. , June 11 , 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chr...
Nevro Announces New Employee Inducement Grants Under NYSE Rule 303A.08 PR Newswire REDWOOD CITY, Calif. , May 24, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the trea...